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Prostate cancer is a heterogeneous malignancy, with clinical courses widely differing between indolent
and aggressive lethal disease. This heterogeneity calls for a more personalized approach towards diag-
nosis, prognosis, treatment decision, monitoring and follow-up of patients. In this review, we discuss the
possibilities and drawbacks of detecting RNA biomarkers in biological ﬂuids to improve disease-speciﬁc
survival and quality of life. In particular, we examine literature on long non-coding RNAs in blood and
urine of prostate cancer patients. We thereby speciﬁcally focus on the need for standard operation
procedures on many different levels, analytical validation, clinical validation, and assessment of clinical
utility. We argue that thorough multi-step validation of putative biomarkers is necessary for successful
translation into clinical prostate cancer care. Our recommendations may also prove useful to biomarker
research in other cancers.
© 2018 Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer is not one disease, but a heterogeneous group of malig-
nancies. Even within one cancer type substantial differences exist,
and prostate cancer is no exception to that biological observation.
Indeed, disease heterogeneity is reﬂected by the different clinical
courses of indolent versus aggressive and lethal prostate cancers.
As a matter of fact, the ﬁve-year overall survival of prostate cancer
patients is 98.9% [1], whereas prostate cancer is still the third-
leading cause of death by cancer in men [2]. In other words, the
majority of prostate cancers are not life-threatening, but aggressive
prostate cancers are still estimated to kill more than 29,000 men in
the United States of America in 2018 [3]. This heterogeneity makes
prostate cancer rather difﬁcult to treat and far from a well-
controlled disease, which is also indicated by the fact that only
30% of metastasized cases survive longer than 5 years [3]. This
disease diversity calls for a more personalized approach towards
diagnosis, treatment and follow-up of patients.s, Ghent University, Ghent, Belgiu
elsmoortel).
r B.V. on behalf of KeAi CommunicaLiquid biopsy, a technique that assesses tumor markers in bio-
logical ﬂuids, has the potential to become a low-cost, fast and
minimally invasive tool for personalized clinical care. However, the
detection of clinically useful biomarkers in blood, urine and other
body ﬂuids from cancer patients still has several hurdles to take.
Once researchers overcome the obstacles described in this review,
new liquid biomarkers have the potential to vastly improve today's
clinical care of prostate cancer patients. After summarizing the
expectations and limitations of biomarkers and liquid RNA biopsies,
we review current literature on long non-coding RNAs (lncRNAs) in
body ﬂuids from prostate cancer patients. LncRNAs are RNA mol-
ecules that do not code for proteins and are longer than 200 nu-
cleotides [4]. They play an important role in many cancer-related
biological processes, from regulation of proliferation to metastasis
[5]. Notably, several lncRNAs show a tissue- or cancer (sub)type-
speciﬁc expression pattern, which makes them excellent candidate
biomarkers for personalized medicine [6]. A general overview of
the topics discussed in this review article is depicted in Fig. 1.m.
tions Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://
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biomarkers?
In general, good biomarkers can be used for cancer screening,
diagnosis, prognosis, treatment decisions and monitoring of cancer
patients during/after treatment [7].
Prostate cancer screening. Heated debates have been held over
the beneﬁts-to-harms ratio of prostate cancer screening using
prostate speciﬁc antigen (PSA)-levels in serum. Current recom-
mendations advise against the use of population-based PSA-
screening for prostate cancer and stress the importance of shared
decision-making [8]. The results of the two large PLCO (Prostate,
Lung, Colorectal, and Ovarian Cancer Screening Trial) and ERSPC
(European Randomized Study of Screening for Prostate Cancer)
trials suggest that the beneﬁts of PSA-screening currently seem not
to outweigh the harms, although one study showed contamination
because patients in the control arm also underwent screening [8].
In particular, up to 75% of the biopsies executed after increased
serum PSA-levels reveal no cancer at all [9]. These unnecessary
biopsiesewhich are the result of PSA being prostate-speciﬁc rather
than prostate-cancer speciﬁc e have important emotional and
physical side-effects such as infection, hematospermia, hematuria
or rectal bleeding [10]. In addition, biopsies very often detect low-
grade disease that would rather beneﬁt from active surveillance
instead of intense treatment [11]. However, over-diagnosis and
overtreatment of clinically insigniﬁcant prostate cancer that will
never cause any impairment to the patient is a problem and should
be avoided. The entire PSA screening controversy is beyond the
scope of this article, but new liquid biomarkers for primo-diagnosis
able to distinguish between prostate cancer and other (benign)
prostate diseases on the one hand, and between indolent and
aggressive disease on the other hand could shed an entirely new
light on the (dis)advantages of prostate cancer screening. By all
means, any cancer screening should reduce cancer-speciﬁc mor-
tality and, albeit more challenging, overall mortality [12].
Diagnosis. The gold standard for prostate cancer diagnosis is a
needle core biopsy, often performed after increased PSA-levels or
suspicious digital rectal exam. However, biopsies can miss up to
28% of all prostate cancers [2]. By deﬁnition, a needle core biopsy
only investigates small parts of the prostate gland, which augments
the likelihood of false-negative results. Systemic, liquid biomarkers
have the potential to circumvent this problem.
Prognosis. Currently, one of the strongest prognostic factors for
prostate cancer outcome is the Gleason-score that is based on the
microscopic architecture and appearance of cells in biopsy tissue
[13]. The score is calculated by grading the predominant histolog-
ical pattern and the highest pattern on a scale from 1 to 5. An
(updated) Gleason score of 3 þ 3 corresponds to a very low-risk
grade 1 cancer, whereas high-risk grade 5 cancers have Gleason
scores of 4þ 5, 5þ 4 or 5þ 5. Three other risk groups lie in between
these two extremes. However, scoring based on biopsy tissue poses
the threat of under-grading in up to 17% of cases because of
inherent sampling error [2]. Indeed, due to tumor heterogeneity or
multifocal lesions, Gleason scores may sometimes not reﬂect the
true aggressiveness of the tumor. In addition, the development of
clinically useful tests to clearly and unambiguously predict the
future course of the disease is still a work in progress. Again, new
liquid biomarkers could overcome the fact that a tissue biopsy only
captures a fraction of the tumor.
Treatment decisions. In contrast to prognostic biomarkers, which
inform about outcome independent of the treatment received,
predictive biomarkers provide information on the likely beneﬁt
from treatment [14,15]. However, biomarkers predictive of treat-
ment toxicity and/or therapeutic effectiveness are largelyunexplored [1]. New disease (sub)type-speciﬁc liquid biomarkers
could help guide the decision of whether to choose for active sur-
veillance, surgery, (adjuvant) radiation therapy, androgen depri-
vation therapy, chemotherapy, immunotherapy and/or newly
developed targeted therapies.
Monitoring and follow-up. Finally, closely monitoring the effect
of a certain therapy, especially in aggressive metastatic castration-
resistant prostate cancer (mCRPC), is extremely valuable [16]. Early
prediction of treatment failure or relapse and indications when to
switch gears could e obviously together with the development of
new therapies e reduce future prostate cancer-speciﬁc mortality.
Minimally invasive tests based on liquid biomarkers for therapy
monitoring promise to be affordable and fast, and make it possible
to evaluate tumor marker levels on a regular, serial basis. In addi-
tion, follow-up of patients who received local treatment (such as
external radiotherapy, brachytherapy or focal therapy) is currently
not straightforward. The PSA bounce phenomenon, for instance,
often leads to uncertainty and needless additional clinical tests that
could be avoided with better liquid biomarkers.3. On the need for biomarker validation and adequate
reporting
Biomarkers, both liquid and non-liquid, can be powerful tools in
the personalized care of cancer patients. However, the biomarker
ﬁeld has to deal with two main issues. On the one hand, there is a
superﬂuity of putative biomarkers reported in scientiﬁc literature
that never make it to the clinic. On the other hand, some biomarker
tests that were never proven to improve patient care are
commercially available [7,17]. Both are the result of a vicious cycle,
tremendously well described by Daniel Hayes and colleagues,
where poor reporting, inadequate funding and the absence of
biomarker validations are all interconnected [18].
Notably, whatever the use of a speciﬁc biomarker test will be,
new tests should be analytically validated, clinically validated and
their clinical utility should be demonstrated before applying them
in routine clinical practice. As reviewed last year in the context of
RNA sequencing by Byron and colleagues, analytical validation re-
fers to the accuracy and reliability of a certain test to measure a
speciﬁc biomarker molecule [19]. In other words: how well does
the test measure the speciﬁc biomarker of interest? Important
factors to assess are, amongst others, analytical sensitivity, analyt-
ical speciﬁcity, repeatability and reproducibility [19]. Subsequently,
if a biomarker can be measured accurately in a reliable way, the
clinical validity of the test should be evaluated. How well does the
biomarker detect or predict a clinical diagnosis or outcome? Key
factors here are clinical sensitivity, clinical speciﬁcity, and positive
and negative predictive value. Finally, and most importantly, a
biomarker test should inform clinical decisions and improve dis-
ease outcome, which is indicated by the level of clinical utility.
However, and in contrast to the more rigorous safety and efﬁcacy
regulations before new drugs hit the market, the regulatory envi-
ronment for commercial use of tumor biomarker tests e especially
when it comes to clinical utility e is much less clear [7]. As will be
described below, only a minority of lncRNAs reported to be
detectable in body ﬂuids of prostate cancer patients has been
investigated on these three levels to date. Clearly, to unleash the full
potential of biomarkers in personalized cancer care, both in-
vestigators, scientiﬁc journals, funding agencies and regulatory
agencies urgently need to improve research quality by thoroughly
thinking through study designs, by stimulating and striving to-
wards reproducible results and by conducting all necessary vali-
dation tests.
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Cancer biomarkers that are detectable in body ﬂuids undeniably
have great potential, and liquid biopsies are emerging as an
extremely attractive application of this potentiality. As a matter of
fact, tumors are known to shed different types of tumor-derived
molecules in body ﬂuids: cell-free DNA, RNA (fragments) and
proteins, circulating tumor cells, extracellular vesicles, etc. [20].
Assessing the levels of these markers in liquid biopsies has the
potential to add a new, minimally invasive layer to the diagnosis,
treatment and follow-up of prostate cancer patients. Next to being
easy, low-cost and fast, liquid biopsies are in principle able to
overcome tumor heterogeneity or the multifocal nature of certain
tumors by taking a more systemic view. Finally, a liquid snapshot of
the tumor can be obtained repeatedly, as many times as needed
[21]. We expect that the implementation of liquid biopsies in
clinical prostate cancer care might be even smoother compared to
some other cancers. First, prostate cancer has a long history with
blood-based PSA tests. Second, the likelihood of detecting tumor
markers before radical prostatectomy in urine, a body ﬂuid very
easy to collect, is quite high because of the anatomical location of
the prostate.
RNA has substantial advantages over DNA when it comes to
investigating disease biology in order to develop new biomarkers.
First, RNA expression is by deﬁnition dynamic and ﬂuctuates ac-
cording to the internal needs of a (cancer) cell. Second, the
expression pattern of several RNA molecules or fragments thereof,
in particular lncRNAs, is highly tissue- or disease-state-speciﬁc [6].
Finally, focusing on RNA also allows the investigation of non-coding
RNAs, fusion transcripts, splice variants and RNA editing events
[22]. Identifying which cancer (sub)type a particular patient is
confronted with, in which stage the cancer is and which treatment
will yield the best results is considered the Holy Grail of cancer
biomarker research [23]. Because of their speciﬁcity, especially
lncRNAs detectable in body ﬂuids have the potential to meet the
expectations, but some essential obstacles still need to be tackled.
Indeed, although many putative liquid RNA biomarkers have
been published, the RNA liquid biopsy ﬁeld currently struggles with
too many pre-analytical variables that have never been rigorously
tested. In particular, it is very well possible that different factors
(such as time of blood draw, blood collection tube, needle, diet of
the patient, blood fraction (e.g. platelet-rich plasma, platelet-free
plasma, platelets, etc.), RNA isolation protocol, and many others)
inﬂuence RNA abundance levels in body ﬂuids, both inside and
outside extracellular vesicles [24]. Therefore, we believe there is an
urgent need for standardization of sample collection, RNA isolation
and data-analysis. As a matter of fact, we consider standard oper-
ating procedures as an extremely important prerequisite before
liquid RNA biopsy research can be translated in clinically useful
applications.
To standardize the use of lncRNAs in liquid biopsies we suggest
ﬁrst setting up comprehensive RNA sequencing studies to assess
the impact of different pre-analytical variables in a controlled and
systematic way. Sequencing plasma fractions that were collected
and prepared in various ways will provide valuable information on
the effect of numerous factors on lncRNA abundance, quality,
fragmentation and yield. Factors we expect to have a substantial
inﬂuence are the blood collection tube, time between collection
and plasma preparation, plasma type (number and intensity of
centrifugation steps), RNA isolation method, storage conditions,
etc. Afterwards, all results should be made available in a public
databasewhere researchers can track the inﬂuence of different pre-
analytical variables on their lncRNA(s) of interest. Based on the
collaborative efforts of the liquid biopsy research community, in-
ternational guidelines to study lncRNA biomarkers can then beimplemented. It should be noted that the ideal protocols and pro-
cedures will likely depend on the intended application. Our lab is
currently coordinating the extracellular RNA quality control study
(exRNAQC) in which many of the aforementioned experiments will
be conducted.
Finally, technological improvements for RNA quantiﬁcation are
still needed. For instance, total RNA sequencing (to detect both
coding and non-coding RNA) and extracellular vesicle isolation
methods are still difﬁcult to implement in many research labora-
tories and would beneﬁt from further technological improvement,
especially when these methods will have to be implemented in
future routine clinical practice.
5. LncRNAs in prostate cancer body ﬂuids
A literature search for lncRNAs detectable in body ﬂuids of
prostate cancer patients, based on the keywords speciﬁed in the
methods section, returned 28 articles. In these articles, 17 so-called
lncRNAs are described to be detectable in blood or urine of prostate
cancer patients. Of note, SPINK1 [25] and PTI-1 [26] e at some point
described as non-coding RNAs e should be classiﬁed as protein-
coding genes according to Ensembl hg38 and GeneCards [27,28].
The other lncRNA genes are listed in Table 1.
Some of these lncRNAs play an important role in prostate cancer
progression and metastasis, and have been intensely researched in
tissue samples or as potential therapeutic targets. However, in this
review we mainly focus on the detection in body ﬂuids and
investigate to which level these putative lncRNA biomarkers are
analytically and clinically validated in blood or urine.
The speciﬁc role and function of these lncRNAs in prostate
cancer malignancy is reviewed elsewhere [25,26,29]. As a matter of
fact, it is not necessary to know the exact function of a molecule for
it to be a good biomarker. To describe the amount of lncRNAs
detectable in body ﬂuids, we deliberately choose to talk about
‘levels’ or ‘abundance’ instead of ‘expression’. In our opinion,
expression refers to an active endogenous cellular process, while
body ﬂuids rather contain lncRNAs than actively expressing them. It
should also be noted that lncRNA fragments can be detected in
body ﬂuids and extracellular vesicles, adding an additional layer to
data-analysis of RNA sequencing experiments.
5.1. An important note on lncRNA nomenclature
Because lncRNA names are not as standardized as is the
nomenclature for coding genes, we intended to use LNCipedia 5.0
IDs for all lncRNAs described in this review [4]. However, when
identifying lncRNA locations by UCSC in silico PCR using the
primers described in the respective articles, we made some inter-
esting observations.
First, the amplicon generated by the MALAT1 primers overlaps
with a lncRNA exon on the opposite strand [30]. Because classical
RT-qPCR (in contrast to strand-speciﬁc RT-qPCR) cannot make a
distinction between sense and antisense transcripts, it is possible
that theMALAT1 primers also amplify lnc-LTBP3-2. The same is true
for PCAT18, whose amplicon overlaps with the antisense lncRNA
AQP4-AS1 [31].
What is more, MD-miniRNA (short for MALAT1-derived mini-
RNA) is described as an independent lncRNA in literature [32,33].
Notably, the same research group published two different articles,
one on MALAT1 and one on MD-miniRNA. However, the same
primer pair was used to detect both genes. We argue that MD-
miniRNA should not be given a separate name and should be
identiﬁed as MALAT1.
Next, the amplicon generated by both primers for FR0348383
does not overlap with any coding or non-coding exon in LNCipedia
Table 1
Overview of circulating lncRNAs in prostate cancer. PCa¼ prostate cancer, BPH¼ benign prostatic hyperplasia, ROC¼ receiver operating characteristic, AUC¼ area under the curve, DRE¼ digital rectal exam, PSA¼ prostate-
speciﬁc antigen, mCRPC¼metastatic castration-recurrent prostate cancer.
gene reference ﬂuid samples main ﬁndings liquid lncRNA analytical validation clinical validation clinical utility normalization
PCA3 Nicholson
et al., 2015
post-DRE
urine
meta-
analysis
prostate-cancer speciﬁc expression extensively
assessed
extensively assessed assessed meta-analysis
MALAT1 Ren et al.,
2013
plasma
and serum
8 PCa/25
PCa/87 PCa
vs. 82 BPH
vs. 23
healthy
stably detectable in plasma, able to
discriminate between PCa and non-PCa,
and between PCa and BPH; higher in PCa
stability (freeze/
thaw, incubation
time, storage time,
acid-base
treatment, RNase
degradation).
tumor source, xenograft presence, ROC/AUC,
sensitivity, speciﬁcity.
not assessed ﬁxed liquid/
RNA volume
MALAT1 Xue et al.,
2015
plasma 63 PCa, 32
BPH, 50
healthy
able to discriminate PCa from healthy
controls and PCa from BPH, higher in PCa;
panel of MD-miniRNA and PSA has better
performance
not assessed ROC/AUC not assessed b-actin
MALAT1 Wang
et al., 2014
post-DRE
urine
218
(discovery),
216
(multicenter
validation)
MALAT1 score signiﬁcantly higher inmen
with positive biopsy compared to
negative biopsy; could avoid up to 47%
avoidable biopsies in PSA grey zone
without missing any high-grade cancers
not assessed detection rate; AUC in univariate regression
analysis and predictive accuracy and AUC in
multivariable regression, in both overall
patient group and PSA grey zone; Everything
in discovery and validation cohort
net beneﬁt, net reduction in avoidable
biopsies, missed (high-grade) prostate
cancers in both overall patient group
and PSA grey zone; everything in
discovery and validation cohort
normalisation
intrinsic to
calculation of
the score
FR0348383 Zhang
et al., 2015
post-DRE
urine
213 cases
with
PSA> 4 ng/
ml and/or
abnormal
DRE
high FR0348383 score correlated with
probability of positive biopsy; could
avoid up to 52% biopsies without missing
any high grade cancers in PSA grey zone
cohort
three different
urine collections?
detection rate; predictive accuracy of
variables in univariate and multivariable
regression, ROC/AUC, in entire cohort and
PSA grey zone cohort
net beneﬁt, net reduction in avoidable
biopsies, missed (high-grade) prostate
cancer numbers in PSA grey zone
cohort
normalisation
intrinsic to
calculation of
the score
SCHLAP1 Prensner
et al., 2014
post-DRE
urine
256 higher expression in Gleason 7 vs.
Gleason 6, and higher levels in high-risk
vs. low-risk
not assessed not assessed not assessed GAPDH/KLK3
average
GAS5 Isin et al.,
2015
exosomes
from post-
DRE urine
30 PCa, 49
BPH
detected, but no difference between PCa
and BPH
not assessed not assessed not assessed GAPDH
lincRNA-p21 Isin et al.,
2015
exosomes
from post-
DRE urine
30 PCa, 49
BPH
signiﬁcant higher levels in PCa compared
to BPH
not assessed sensitivity and speciﬁcity. not assessed GAPDH
PCAT18 Crea et al.,
2014
plasma 25 healthy,
25 primary
PCa, 25
mCRPC
signiﬁcant incremental increase from
healthy individuals to primary PCa to
mCRPC
not assessed not assessed not assessed GAPDH and
HPRT
AK024556,
XLOC_007697,
LOC100287482,
XLOC_005327,
XLOC_008559
and
XLOC_009911
Lee et al.,
2014
urine 13 PCa, 14
healthy
all six markers detected in urine, up-
regulated compared to healthy urine
not assessed not assessed not assessed GAPDH
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H. Helsmoortel et al. / Non-coding RNA Research 3 (2018) 64e7468or RefSeq, and thus no corresponding LNCipedia ID could be
identiﬁed [34]. Raw RNA sequencing data from the experiment
seem not to be publicly available to check for transcripts or reads
ourselves.
In addition, lincRNA-p21 is known as a murine gene and the
amplicon also seems not to overlap with any exon in the human
hg38 build, because of which no corresponding LNCipedia ID
could be identiﬁed [35]. However, in 2010 the lab of John Rinn
investigated the locus in the human genome and designed
primers that ampliﬁed human sequences, which were used in the
article described in this review [36].
Finally, six lncRNAs are described using identiﬁers corre-
sponding to speciﬁc microarray probes [37]. Because identical
identiﬁers can match different genes in various microarray and
RNA sequencing experiments, we do not recommend using them
in published articles. Instead accession numbers or sequences
should be provided. For one lncRNA, AK024556, the authors
mention the alternative gene name SPRY4-IT1, which corresponds
to LNCipedia ID lnc-FGF1-9 in the current release. For the other
ﬁve lncRNAs, we looked up the probe sequence (using online
Agilent SurePrint G3 Human GE v2 probe information) and used it
as input for LNCipedia searches, returning ﬁve gene names.
XLOC_007697 corresponds to lnc-SPATA31A6-6, XLOC_005327 to
LINC01564, XLOC_008559 to lnc-RPP30-2 and XLOC_009911 to
lnc-HNF1A-1. One microarray probe however, LOC100287482,
corresponds to the protein coding gene SMK1.
In conclusion, since this is a literature review, we decided to
report both the gene names used in the respective articles and the
corresponding LNCipedia IDs. Yet, we want to signal our nomen-
clature observations to the scientiﬁc community and recommend
to critically investigate the locations, sequences and names of the
lncRNAs in question before conducting any further experiments.
An overview of the primer andmicroarray probe sequences can be
found in Table 2.
5.2. PCA3
PCA3 is without a doubt the most widely studied lncRNA in
body ﬂuids of prostate cancer patients. Prostate cancer-speciﬁc
overexpression of PCA3 (DD3) was ﬁrst described by Busse-
makers and colleagues in 1999 [38]. In 2012, the American Food
and Drug administration (FDA) approved the Progensa PCA3 urine
test for helping clinicians whether or not to recommend a repeat
biopsy after a negative biopsy result [39]. In addition, the test
received a CE-mark for use in the European Union [40]. An inde-
pendent meta-analysis of the analytical validity, clinical validity,
clinical utility and cost-effectiveness of the urine PCA3 test is way
beyond the scope of this review article.What is more, an extensive
192-page long report that investigated all four topics above was
published in 2015 [40]. In short, analytical validity was reviewed
using six studies, indicating that there were issues with the pre-
cision of the PCA3 measurements. Fifteen studies assessing clin-
ical validity indicated insufﬁcient evidence to identify appropriate
threshold values for clinical use. In addition, the test did not
improve discrimination compared to clinical assessment and
magnetic resonance imaging. No studies were found analyzing
clinical utility and cost-effectiveness. Therefore, the authors of the
report built a de novo model indicating that the PCA3 test had no
value for money for UK's National Health Service. In conclusion,
the report could not conﬁrm the clinical beneﬁt of the PCA3 assay.
Consequently, the National Institute for Health and Care Excel-
lence does not recommend the test in men who already had a
negative (or unclear) prostate biopsy.
In addition, a recommendation from the Evaluation of
Genomic Applications in Practice and Prevention (EGAPP)
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urine test adequate, although very few studies investigated pre-
analytical effects, analytical performance, and diagnostic accuracy
of other quantitative assays for PCA3. In contrast to the analytical
validity, the clinical validity was rated inadequate to inform de-
cisions about initial or repeat biopsy [41]. No clinical utility studies
could be identiﬁed. Although the evidence seems to indicate
insufﬁcient advantage of the PCA3 kit, the test is still sold and used
bymany clinicians worldwide. These results exemplify the extreme
importance of validating biomarkers on different levels, and in
multiple independent studies. In addition, convincing clinicians to
assess results of validation studies critically instead of blindly
following recommendations from pharmaceutical or diagnostic
companies is not always straightforward.
5.3. MALAT1 (or MD-miniRNA)
PolyA þ RNA sequencing of 14 prostate cancer tissues and their
adjacent normal tissues revealed on average 406 differentially
expressed lncRNAs in the 14 different comparisons, including PCA3
and MALAT1 [42]. MALAT1 was found to be overexpressed in 82.5%
of prostate cancer compared to normal tissues. In a follow-up study,
the same research group tried to validate the presence of MALAT1
and PCA3 in additional tissue samples, and in plasma from eight
prostate cancer patients. For the latter part, RT-qPCR primer pairs
for nine different amplicons were developed.
The authors identiﬁed high plasma levels of one amplicon in
particular and named it MD-miniRNA (short for MALAT1 derived
miniRNA). A similar result was obtained for a PCA3 amplicon, in the
article called PCA3 derived miniRNA, or PD-miniRNA. Assuming that
higher abundant transcripts play a more important role, further
validation experiments in plasma were carried out with MD-mini-
RNA and PD-miniRNA only. As described above, the authors of this
review propose to use MALAT1 and PCA3, respectively, instead.
Interestingly, the authors investigated the plasma abundance
stability in 13 patients by varying freeze/thaw cycles, incubation
times at room temperature, storage times in 80 C freezers, acid-
base treatments, and RNase degradation assays. Strikingly, none of
these ﬁve variables seemed to have a signiﬁcant inﬂuence on
plasma RNA levels. By proving that both of the plasma lncRNA
fragments are stable, detectable and RNase degradation-resistant,
the authors assess many of the pre-analytical variables that are
largely ignored in liquid biopsy studies today. What is more, the
levels of the lncRNA fragments were compared in parallel samples
of EDTA plasma, heparin plasma and serum of 12 additional pa-
tients. The results revealed that fragments are largely undetectable
in heparin tubes but can be measured in EDTA plasma and serum,
although the detected levels are not correlated in both blood
fractions.
Because of low diagnostic power of PD-miniRNA, the authors
further only validate MD-miniRNA as possible blood-based
biomarker for prostate cancer. After evaluating the presence of
MD-miniRNA in blood of xenografted mice, MD-miniRNA levels
were assessed in 10 additional prostate cancer patients before and
7 days after surgery to verify that the lncRNA fragment is derived
from prostate tumors. Indeed, in all patients but one, the MD-
miniRNA levels declined after surgery with approximately 10-fold
magnitude. Finally, the clinical validity of MD-miniRNA to discrim-
inate 1) between prostate cancer (PCa) and non-PCa, 2) between
prostate cancer and benign prostate hyperplasia (BPH) in patients
with PSA> 4 ng/ml and 3) between prostate cancer and BPH in
patients with PSA levels between 4 and 10 ng/ml was evaluated.
Therefore, RT-qPCR levels of plasma MD-miniRNA were measured
in 87 prostate cancer patients with positive biopsy, 82 BPH patients
with negative biopsy and 23 healthy controls, followed by receiveroperating characteristics (ROC) curve analysis comparing serum
PSA to plasma MD-miniRNA. The results indicate a slightly higher
area under the curve (AUC) for MD-miniRNA in all three settings.
Indeed, when comparing plasma MD-miniRNA with serum PSA,
AUCswere respectively 0.836 vs. 0.770, 0.841 vs. 0.708 and 0.767 vs.
0.446 in the three settings described above. In addition, sensitiv-
ities of 58.6%, 58.6% and 43.5%, and speciﬁcities of 84.8%, 84.1% and
81.6% were calculated at a detection cut-off of 867.8 copies of MD-
miniRNA per microliter, altogether illustrating that plasma MD-
miniRNA might be a promising indicator for discriminating be-
tween PCa and non-PCa, and between prostate cancer and BPH,
especially in the PSA grey zone (PSA between 4 and 10 ng/ml).
In an independent study, plasma MD-miniRNA was measured
using RT-qPCR in a cohort of 63 prostate cancer patients, 32 BPH
patients and 50 healthy controls [33]. ROC curve analysis with AUC
showed that MD-miniRNA was better able to discriminate prostate
cancer from healthy controls on the one hand, and prostate cancer
from BPH on the other hand. MD-miniRNA performed better than
serum PSA, but the combined panel of the two had the best diag-
nostic performance. AUC values for prostate cancer vs. control were
0.73 for serum PSA, 0.86 for MD-miniRNA and 0.89 for the panel.
AUC values for prostate cancer vs. BPH were 0.66 for serum PSA,
0.79 for MD-miniRNA and 0.82 for the combination of both.
Although ROC curves are interesting tools to mutually compare
tests, p-values should also be reported. What is more, clinical
implementation of biomarker tests also requires the determination
of a speciﬁc cut-off value, with associated sensitivity and speciﬁcity
values (and other relevant parameters) e which were not deter-
mined by the authors.
In conclusion, while the clinical utility of plasma MD-miniRNA
remains to be proven, at least several analytical and clinical vali-
dations are in place. Larger, non-Asian, multicenter study cohorts
are needed to further validate the results. On a more molecular
level, novel RNA sequencing technologies are also likely to shed
additional light on the fragmented abundance of lncRNAs in body
ﬂuids.
As mentioned above, Ren and colleagues performed
polyA þ RNA sequencing on 14 pairs of prostate cancer tissue and
adjacent normal tissue, amongst others revealing several differ-
entially expressed lncRNAs [42]. In another retrospective and pro-
spective follow-up study, the authors sought to evaluate lncRNA
MALAT1 levels in urine samples as a diagnostic biomarker for
prostate cancer [30]. Therefore, urinary RT-qPCR levels of MALAT1
and PSA were analyzed in a discovery cohort of 218 patients and a
multicenter validation cohort of 216 patients, all scheduled for
prostate biopsy because of elevated PSA levels (PSA> 4 ng/ml) and/
or suspicious digital rectal exam (DRE). Subsequently, the MALAT1
score was calculated as (MALAT1 RNA/PSA mRNA) x 1000. This is
similar to 2Cq(PSA)-Cq(MALAT1) x 1000 (with Cq being the RT-qPCR
quantiﬁcation cycle). Of note, our comparison of the primer se-
quences revealed that the authors amplify the same MD-miniRNA
amplicon as in the article above, although they consistently use the
gene name MALAT1 throughout the article.
The MALAT1 score was signiﬁcantly higher in patients with a
positive biopsy compared to negative biopsies, in both the overall
discovery patient group and in a subgroup of patients with PSA
levels in the grey zone. In addition, prostate cancer detection rates
in subjects with low, intermediate, high and very high MALAT1
scores were reported. Comparable results were obtained in the
validation cohort.
Next, univariate analyses were included for different variables
(MALAT1 score, age, total PSA, percentage free PSA, etc.) and the
area under the curve (AUC) for each variable was reported in both
the overall discovery patient group and the PSA grey zone sub-
group. Subsequently, two different multivariable models (one with
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curacy and AUC values, revealing that the model including the
MALAT1 score performed slightly better in both the entire patient
group and the PSA grey zone subgroup. AUCs were 0.815 for the
model without MALAT1 score vs. 0.840 for the model with MALAT1
score in the entire patient group and 0.821 vs. 0.853 in the PSA grey
zone subgroup. The results could all be validated, with AUCs of
0.817 vs. 0.833 in the entire validation cohort and 0.772 vs. 0.779 in
the PSA grey zone subgroup of the validation cohort.
A hint towards clinical utility is given by decision curve analysis
where the net beneﬁt and net reduction in avoidable biopsies are
calculated for 7 different levels of threshold probabilities, ranging
from 10% to 40%. Threshold probabilities reﬂect the theoretical
point at which a patient would decide to undergo a certain pro-
cedure, because from that level on the beneﬁts outweigh the
harms. For instance, a cut-off value of 25% implies that a patient
would decide not to be scheduled for prostate biopsy when he was
told he had an estimated probability of less than 25% of having
prostate cancer. Conversely, the patient would take the biopsy if his
estimated probability of prostate cancer was equal to or higher than
25% [43]. The authors focus on patients in the PSA grey zone, while
results for the entire group are described in supplementary ﬁles. In
addition, the numbers of missed prostate cancers and high-grade
prostate cancers are reported for threshold probabilities between
15% and 40%. At a cut-off value of 25%, the model includingMALAT1
score could avoid slightly more unnecessary biopsies, while
missing the same number or fewer cancer diagnoses, depending on
whether looking at the discovery or validation cohort. Notably, the
differences in avoidable biopsy percentages strongly differ between
discovery and validation cohort (47% vs. 30%), pointing towards the
importance of including an independent cohort in biomarker
validation studies. Finally, sensitivity and speciﬁcity were
compared between MALAT1 score and percentage free PSA at
speciﬁc cut-off values. In the discussion, the authors mention four
shortcomings in their study design: relatively small sample size, no
comparison with PCA3 score (due to the PCA3 kit not being avail-
able in China), no comparison with existing nomograms and not
taking into account whether patients undergo a ﬁrst or repeat bi-
opsy. Further, large-scale studies including additional (analytical
and clinical) validation will indeed be needed to conﬁrm the ﬁnd-
ings. As a side note, the authors mention that MALAT1 is also re-
ported to be involved in other cancer types (hepatocellular
carcinoma, lung adenocarcinoma, colorectal cancer, etc.). One
should be careful with clinical implementation of so-called ‘spe-
ciﬁc’ lncRNA biomarker tests, as patients with increased serum PSA
levels and a positive (hypothetical) MALAT1 test could, in theory,
suffer from another cancer in combination with BPH, for instance.
Therefore, pan-cancer-wide screening of putative lncRNA bio-
markers should be an additional validation step.
5.4. FR0348383
As already described, Ren and colleagues previously revealed
several differentially expressed lncRNAs after RNA sequencing 14
pairs of prostate cancer tissue and matched adjacent normal tissue
from patients who underwent radical prostatectomy [42]. In a third
follow-up study, the same group investigated whether one of the
top differentially expressed lncRNAs, FR0348383, could have
diagnostic value in urine samples [34]. Again, ﬁrst-catch urine
samples after DRE were collected from patients scheduled for
prostate biopsy because of elevated PSA (PSA> 4.0 ng/ml) and/or
abnormal DRE results. The FR0348383 score, being the ratio of PSA
and FR0348383 mRNA measured by RT-qPCR multiplied by 1000,
was calculated in 213 patients whose urine samples contained
sufﬁcient RNA.An increasing FR0348383 score was signiﬁcantly correlated
with an increasing probability of a positive biopsy. In addition,
prostate cancer detection rates and univariate and multivariable
regression analysis with predictive accuracy of each variable were
described, the latter both for the entire cohort and for a sub-cohort
of patients with grey zone PSA. The authors applied similar clinical
validation experiments as in their previous article to assess
whether FR0348383 score, PSA, PSA density (the ratio of PSA level
and prostate volume) and percentage free PSA could accurately
discriminate between patients with and without prostate cancer.
ROC curve analyses and AUC calculations for the entire cohort
revealed that FR0348383 score and PSA were comparable (AUC of
0.760 vs. 0778, p¼ 0.740). In the PSA grey zone cohort, FR0348383
(AUC: 0.815) signiﬁcantly outperformed PSA (AUC: 0.562,
p¼ 0.020) and percentage free PSA (AUC: 0.599, p¼ 0.039), while
FR0348383 score AUC was higher but not signiﬁcantly different
compared to PSA density (AUC: 0.645, p¼ 0.124). The combination
of FR0348383 score and PSA density had the highest AUC (0.876),
but was not statistically different from FR0348383 score alone.
Subsequently, net beneﬁt, net reduction in avoidable biopsies
and number of missed (high-grade) prostate cancers were reported
for six different threshold probabilities, ranging from 15% to 40%.
These decision curves revealed that the FR0348383 score could
save 52% of avoidable biopsies in patients with grey zone PSA at a
threshold probability of 30%, without missing any high-grade
prostate cancer. What is more, the authors state in their methods
section that three different urine samples of all patients were
collected to demonstrate reliability and concordance of the
biomarker. However, it is not entirely clear how these triplicates are
handled in the article. In conclusion, the authors clearly value the
importance of biomarker validation, but severe analytical valida-
tion of the test itself was not performed and some additional levels
of clinical validation and clinical utility (such as another (blinded)
sample set, prospective trial design, multicenter design, measuring
impact on patient care, etc.) remain to be conducted.
5.5. SCHLAP1
Prensner and colleagues performed microarray experiments in
960 tissue samples from prostate cancer patients treated with
radical prostatectomy. They identiﬁed lncRNA SCHLAP1 as the
highest-ranked overexpressed gene in cancers with metastatic
progression compared to non-metastatic cases [44]. Several ex-
periments and analyses were performed to investigate the prog-
nostic value of SCHLAP1 expression in tissues, in order to identify
patients at high risk formetastatic disease progression. Also urinary
levels of SCHLAP1 were assessed in 230 post-DRE urine samples.
Apart from correlating SCHLAP1 levels with Gleason score and risk
group, no biomarker validations were performed. It is clear that,
although the prognostic value of SCHLAP1 in tissue samples yielded
promising results, further optimization for a possible use as
biomarker in urine is still needed. This limitation is also compre-
hensively acknowledged by the authors.
5.6. GAS5 and lincRNA-p21
Isin and colleagues collected urine samples after digital rectal
exam of 30 prostate cancer patients and 49 patients with BPH [35].
Subsequently, ‘exosomal’ RNA was extracted using the Norgen
Biotek “urine exosome RNA isolation kit”. Of note, the authors do
not describe any quality control of the isolated extracellular vesicles
by western blot, electron microscopy or nanoparticle character-
ization. Yet, evaluation and reporting of exosome quality control is
vital for research in the ﬁeld of extracellular vesicles [45]. Although
we cannot be entirely sure that the reported lncRNAs reside inside
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GAS5 levels were similar in urine of prostate cancer and BPH
patients, whereas the authors report a statistically signiﬁcant
higher lincRNA-p21 abundance in prostate cancer compared to BPH.
Perhaps a limitation for a robust biomarker, the RNA levels of
lincRNA-p21 are very low. AUC was calculated for lincRNA-p21
(0.663) and the (clinical) sensitivity and speciﬁcity to discriminate
BPH from prostate cancer were calculated for lincRNA-p21 alone
(sensitivity: 67% and speciﬁcity: 63%) and in combination with PSA
(52% and 94%), the latter achieving higher speciﬁcity. Of note, the
lincRNA-p21 cut-off value was set at 0.181 and the median ‘exoso-
mal’ levels were reported as 0.071 in BPH and 0.163 in prostate
cancer.
5.7. PCAT18
In 2014, Crea and colleagues performed RNA sequencing of two
xenografted cell lines derived from a needle biopsy of the same
prostate cancer patient [46]. Remarkably, the cells display very
different metastatic characteristics when injected in NOD-SCID
mice. Differential expression analysis between the metastatic and
non-metastatic xenograft-derived cell lines revealed several
differentially expressed lncRNAs. The transcript with highest
expression in the metastatic xenograft was named PCAT18 by the
authors. In the article, the levels of PCAT18 are also assessed by RT-
qPCR in plasma of 25 healthy controls, 25 primary prostate cancer
patients and 25 patients with mCRPC. The PCAT18 RNA levels
signiﬁcantly increase from healthy individuals to patients with
primary and subsequently metastatic prostate cancer. While
PCAT18 is proposed as a novel biomarker for metastatic prostate
cancer, no validation experiments are performed to date.
lnc-FGF1-9 (SPRY4-IT1/AK024556), lnc-SPATA31A6-6
(XLOC_007697), SMKR1 (LOC100287482), LINC01564
(XLOC_005327), lnc-RPP30-2 (XLOC_008559) and lnc-HNF1A-1
(XLOC_009911)
Based on differential expression analysis in prostate cancer cell
lines and patient tissue samples, Lee and colleagues described six
so-called lncRNAs for further investigation (lnc-FGF1-9 (AK024556/
SPRY4-IT1), lnc-SPATA31A6-6 (XLOC_007697), SMKR1
(LOC100287482), LINC01564 (XLOC_005327), lnc-RPP30-2
(XLOC_008559) and lnc-HNF1A-1 (XLOC_00991)) [37]. However, one
microarray probe corresponds to the protein coding gene SMKR1.
All markers could be detected by RT-qPCR in urine samples from 13
prostate cancer patients and were signiﬁcantly higher compared to
urine of 14 heathy controls. In addition, there was no signiﬁcant
difference between urine of healthy controls and 9 BPH patients.
Unfortunately, no direct comparison between prostate cancer pa-
tients and BPH patients was shown. Further, no validation tests for
the biomarker(s) were performed.
6. Normalization of biomarker levels
All body ﬂuid lncRNAs in this review were detected using the
reverse transcription quantitative PCR (RT-qPCR) method. When
evaluating RNA expression levels in cellular RNA from tissues or
cells, normalization of the raw Cq values is extremely important to
account for possible variation introduced at various levels, from
differences in extraction yield and input concentration to efﬁciency
of enzymatic reactions [47]. Normalizing to stably expressed
endogenous reference genes is able to eliminate potential bias in a
sample-speciﬁc way. Although many researchers still normalize to
only one reference gene, the MIQE guidelines clearly state thatnormalization against a single reference gene is unacceptable un-
less authors prove that the gene is invariantly expressed under the
experimental conditions described. What is more, the optimal
number and the choice of reference genes should be experimen-
tally determined [48]. Unfortunately, the MIQE guidelines from
2009 are not yet used by the majority of investigators when
designing RT-qPCR experiments.
In contrast to evaluating expression levels in cellular RNA,
normalization of biomarker data in liquid biopsies is somewhat
different. As amatter of fact, RT-qPCR for biomarkers is not aimed at
obtaining the most accurate estimate of ‘real’ expression but rather
at optimizing the discriminatory power of a quantitative test. The
normalization method to be used (if any) is entirely dependent on
whether normalizing raw values improves the performance of a
speciﬁc biomarker test. Alternative to reference genes, it should be
considered to use ﬁxed input volumes of ﬂuid and/or RNA eluate (in
combination with spike-in molecules, see further).
The last column of Table 1 indicates the normalization strategy
for the liquid lncRNAs detected in prostate cancer patients. The
majority of studies use GADPH (either alone or in combination) as
reference gene. One study opted for ﬁxed liquid/RNA input vol-
umes, whereas two other articles from the same research group
calculated (intrinsically normalized) scores based on Cq values of
the lncRNA of interest and PSA.
In addition to evaluating the normalization strategy, we also
plea for the use of exogenous spike-in molecules as processing
controls. Spiking external controls should be part of any biomarker
analytical validation experiment, to get a better grip on variation
introduced during RNA extraction, reverse transcription and qPCR
or any other quantiﬁcation method. In the end, the biomarker(s)
could be normalized using either endogenous reference genes or
exogenous spikes; the normalization strategy that results in best
biomarker performance is clearly most appropriate in that given
experimental setup.
7. Are other lncRNAs detectable in body ﬂuids?
During our search for lncRNAs detectable in body ﬂuids, we
came across several other lncRNAs implicated in prostate cancer
tissue that are not yet reported to be present in blood, urine or
other body ﬂuids. Examples are lncRNAs with LNCipedia IDs
CDKN2B-AS1 (also known as ANRIL), CTBP1-AS, DRAIC, HOTAIR,
Linc00963, Lnc-MX1-1, lncRNA-ATB (no LNCipedia ID), lnc-DLK1-18
(MEG3), NEAT1, PCAT1, PCAT6, PCAT7, PCAT29, PCGEM1, CBR3-AS1,
PRNCR1, SOCS2-AS1 (no LNCipedia ID), and TRPM2-AS
[26,29,49e53]. To make this review complete, we investigated
whether any of these lncRNAs are present in publicly available total
RNA sequencing data from prostate cancer patient liquid biopsies.
Total RNA sequencing is, in contrast to small RNA sequencing and
polyA þ RNA sequencing, also able to detect (non-polyadenylated,
polyA-) lncRNAs in an unbiased way. Because all lncRNAs in Table 1
were detected in urine, plasma, serum or exosomes, we focused our
literature search on these four liquid biopsy types. To our surprise,
we found only one study matching our interests (see Fig. 1) .
In 2016, Nikitina and colleagues performed whole tran-
scriptome proﬁling in urine and plasma samples from 14 prostate
cancer patients and 3 BPH patients [54,55]. Some samples were
collected before and others after treatment. For one patient, all four
sample types are available, i.e. both urine and plasma, before and
after radical prostatectomy. We extracted FASTQ ﬁles from the
publicly available IonTorrent data and quantiﬁed counts and tran-
scripts per million (TPM) using Kallisto [56]. Next, we checked the
levels of the lncRNA genes reported to be involved in prostate
cancer. Only some of the liquid lncRNAs described in this review
were detected in blood and/or urine. What is more, certain lncRNAs
Fig. 1. Graphical overview of the topics discussed in this review article.
Fig. 2. Heat map constructed from publicly available total RNA sequencing data of
lncRNAs known to be involved in prostate cancer. The lncRNAs in light blue were
already described in literature to be detectable in liquids. The lncRNAs in dark blue are
known to be involved in prostate carcinogenesis, but never before described in liquids.
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tients yet, seem to circulate (Fig. 2). As mentioned above, all
lncRNAs in Table 1 were detected in the respective papers using the
RT-qPCR methodology. We expect that optimization of total RNA
sequencing procedures in body ﬂuids will hugely impact the
identiﬁcation of novel biomarkers for prostate cancer.8. Discussion
In this review, we ﬁrst discussed how (novel) biomarkers could
help improve diagnosis, prognosis, treatment decisions, monitoring
and follow-up of prostate cancer patients. We next touched upon
the importance of analytical and clinical validation, adequate
reporting and a well-thought-out study design when investigating
biomarkers. Subsequently, we considered some advantages and
problems concerning liquid RNA biopsies, to ﬁnd out which
lncRNAs are reported to be present in body ﬂuids of prostate cancer
patients in the next paragraph. PCA3 is available as a commercial
test, and MALAT1, FR0348383, SCHLAP1, GAS5, lincRNA-p21, PCAT18,
lnc-FGF1-9 (AK024556 or SPRY4-IT1), lnc-SPATA31A6-6
(XLOC_007697), LINC01564 (XLOC_005327), lnc-RPP30-2
(XLOC_008559) and lnc-HNF1A-1 (XLOC_009911) were all detect-
able in either plasma, serum, urine or urinary ‘exosomes’. While all
of them are proposed as putative biomarkers at some point, the
levels of validation differ widely between studies. Yet, decently
validated biomarkers aremuchmore likely to be included in further
translational studies. There is thus both room for further validation
of known liquid lncRNA biomarkers in prostate cancer, and for
discovery and subsequent validation of novel ones. As a matter of
fact, the future of big data is likely to produce an overwhelming
amount of candidate biomarkers. Utilizing such biomarkers to
reduce cancer mortality and to improve patient quality of life will
largely depend on excellent study designs, analytical and clinical
validation of the tests, demonstration of clinical utility and detailed
reporting to ensure reproducibility.
To illustrate this, we want to highlight the interesting approach
the group of Yinghao Sun employed: after RNA sequencing of 14
matched tumor/normal pairs, they reported validation experi-
ments for four different biomarkers in body ﬂuids (MALAT1, PCA3
and FR0348383), in three follow-up papers. As is obvious from
Table 1, they conduct more clinical and analytical validation ex-
periments than any other published article reporting a putative
liquid biomarker.
As a side note, it might be possible that Sun's group also tried to
validate other biomarkers, without satisfying results. It would be a
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eral, if it was common practice to also report these ‘negative’
ﬁndings in scientiﬁc journals or curated online databases. This
could avoid wasting valuable resources of other researchers who
are trying to investigate exactly the same question, and who will
likely also not report their results if the conclusions are ‘negative’.
At the same time, reproducible research will also rely upon the
use of standard operation procedures on many different levels. For
instance, standardized protocols to prepare blood plasma will be
needed. As a matter of fact, plasma is now prepared with different
blood collection tubes and according to varying centrifugation
steps in labs and clinics. However, lncRNA signals are likely to differ
between platelet-rich plasma, platelet-poor plasma and platelet-
free plasma, all of which can be isolated separately by varying
centrifugation speeds and durations.
On a more biological level, it remains to be elucidated what the
exact source of a speciﬁc cancer-related lncRNA in body ﬂuids is:
does it come from the tumor or is it the result of a more systemic
(immune) response? In addition, current analyses do not indicate if
the lncRNA (fragment) is present in circulating tumor cells or
extracellular vesicles, whether it is complexedwith certain proteins
or if it travels entirely free, either fragmented or not. An interesting
approach could be to compare RNA from total plasma with RNA
isolated from extracellular vesicles of the same patient. Extracel-
lular vesicle RNA research in cancer seems promising because
exosomes by deﬁnition carry a cargo originating from their host
cell, but standardization in isolation methods is urgently needed
[45]. In addition, tumor-educated platelets are now emerging as
new, interesting blood components to search for biomarkers
[57,58]. It goes without saying that also the detection of coding
mRNA can be extremely valuable in the clinical management of
prostate cancer patients. One example is the SelectMDx test to
identify patients at increased risk for aggressive disease, which
measures mRNA levels of DLX1 and HOXC6 in post-DRE urine.
Finally, apart from actions on the researcher's side, the
biomarker ﬁeld would also beneﬁt from the involvement of
‘biomarker experts’ as peer-reviewers. Rather than assigning
manuscripts to reviewers familiar with the biology of the gene or
with the disease under study, at least one expert acquainted with
specialized biomarker statistics and guidelines should be included
in the peer-review process. Whether the research community
already comprises a sufﬁcient number of experts, or whether these
should be educated in specialized teaching programs remains an
open question. In addition, efforts to explain biomarker experiment
design and statistics in a clear, comprehensible way to life science
researchers is without a doubt extremely valuable, since most of
the statistical courses are too theoretical for many biomedical re-
searchers and clinicians.
In conclusion, we are hopeful that detecting carcinogenesis-
related biomarkers in body ﬂuids will improve diagnosis, prog-
nosis, treatment decision, monitoring and follow-up of (prostate)
cancer patients in the near future. However, we are running the risk
of overhyping the promise if putative biomarkers are not appro-
priately validated at different levels, and standardized protocols are
not implemented soon. This will hamper translation into clinical
practice and might ultimately not lead to any reduction in cancer-
related mortality or progress in quality of life.
9. Methods
To identify lncRNAs in body ﬂuids of prostate cancer patients,
we performed a PubMed search using keywords “lncRNA” or “long
non-coding RNA” AND “prostate cancer” AND “serum” or “plasma”
or “circulation” or “circulating” or “urine” or “exosomes” or “CTC”
or “body ﬂuid” or “cell-free” or “extracellular”. The search was lastperformed on Sept 25, 2017, and returned 28 articles. Detailed
reading of these articles led us to more articles on biomarkers,
lncRNAs and prostate cancer, of which themost relevant ones to the
reader are included in the review.
To seek for publicly available total RNA sequencing datasets, we
performed a PubMed search using keywords “total RNA
sequencing” or “RNA sequencing” or “RNA-seq” or “RNAseq” AND
“prostate cancer” AND “plasma” or “urine” or “serum” or “exo-
somes”. Given that RNA sequencing of liquid biopsies is a rapidly
evolving research ﬁeld, we last performed this search immediately
before submitting the review, on December 14, 2017.
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